NCT06065371 2025-12-19
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Henry Ford Health System
Phase 1 Recruiting
Clinical Trials
25 trialsNCT07156058 2025-09-04
MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Recruiting
NCT05239169 2025-05-01
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT06037980 2025-02-17
PURITY
Gruppo Oncologico del Nord-Ovest
Phase 2/3 Recruiting
NCT04720131 2024-01-30
Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.
Beijing Friendship Hospital
Phase 2 Completed
NCT04856761 2022-08-18
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Fudan University
Unknown
NCT04401709 2022-06-15
Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer
Samsung Medical Center
Phase 3 Unknown
NCT03093870 2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3 Completed
NCT03231176 2020-11-19
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
ASLAN Pharmaceuticals
Phase 2 Completed
NCT02773459 2019-09-30
MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
Seoul National University Hospital
Phase 1/2 Completed
NCT02350686 2019-05-20
XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy
Samsung Medical Center
Phase 2 Unknown
NCT03609489 2018-08-09
A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma
First Affiliated Hospital of Guangxi Medical University
Phase 2 Unknown
NCT03082053 2018-06-28
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
ASLAN Pharmaceuticals
Phase 1 Completed
NCT03129074 2018-05-23
Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
ASLAN Pharmaceuticals
Phase 2 Withdrawn
NCT00142480 2018-04-25
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT02558959 2018-02-13
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
Zhejiang University
Phase 2 Completed
NCT01843725 2018-01-31
MOMENTUM1
Jules Bordet Institute
Phase 1 Completed
NCT02720601 2018-01-25
Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
New Mexico Cancer Research Alliance
Phase 2 Withdrawn
NCT01572324 2017-01-04
Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
Peking University
Phase 2 Completed
NCT00868998 2016-05-23
GTX Regimen for Biliary Cancers
Columbia University
Phase 2 Terminated
NCT01530503 2016-02-25
BIT-2
IRCCS San Raffaele
Phase 2 Completed
NCT00630890 2015-09-11
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
University of California, San Francisco
Phase 1 Terminated
NCT00551096 2013-12-25
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
University of Colorado, Denver
Phase 1 Completed
NCT00338988 2012-08-01
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00626158 2012-04-04
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
University of California, San Francisco
Phase 1 Completed